Author: Theresa Rothenbücher

  • Are you relying on your co-investors to do the due diligence?

    “𝗪𝗲 𝗿𝗲𝗹𝗶𝗲𝗱 𝗼𝗻 𝗼𝘂𝗿 𝗰𝗼-𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀 𝘁𝗼 𝗱𝗼 𝘁𝗵𝗲 𝘁𝗲𝗰𝗵𝗻𝗶𝗰𝗮𝗹 𝗱𝘂𝗲 𝗱𝗶𝗹𝗶𝗴𝗲𝗻𝗰𝗲.”It’s something I hear far too often in intro calls. And almost always, it´s followed by a regretful pause. Several VC firms have told me they’re now working to 𝗯𝘂𝗶𝗹𝗱 𝘁𝗵𝗲𝗶𝗿 𝗼𝘄𝗻 𝗲𝘅𝗽𝗲𝗿𝘁 𝗻𝗲𝘁𝘄𝗼𝗿𝗸𝘀 after having poor experiences relying on others to assess the scientific and technical…

  • Quick comment on the revival of the Dire Wolf

    Our time works with hype and media stunts. But what is actually behind the dire wolf story? Ancient DNA can be recovered only in bits and pieces with most of the information gone. If you are highly skilled and lucky, you will be able to obtain some genes that you can work with and use…

  • Trust is the best client feedback.

    Last week, I wrapped up a technology evaluation project for a VC firm. Their feedback: “𝘠𝘰𝘶𝘳 𝘸𝘰𝘳𝘬 𝘸𝘢𝘴 𝘱𝘪𝘷𝘰𝘵𝘢𝘭 𝘪𝘯 𝘶𝘯𝘥𝘦𝘳𝘴𝘵𝘢𝘯𝘥𝘪𝘯𝘨 𝘵𝘩𝘦 𝘴𝘤𝘪𝘦𝘯𝘵𝘪𝘧𝘪𝘤 𝘮𝘪𝘭𝘦𝘴𝘵𝘰𝘯𝘦𝘴, 𝘸𝘩𝘪𝘤𝘩 𝘩𝘦𝘭𝘱𝘦𝘥 𝘶𝘴 𝘵𝘰 𝘥𝘦𝘵𝘦𝘳𝘮𝘪𝘯𝘦 𝘩𝘰𝘸 𝘮𝘶𝘤𝘩 𝘮𝘰𝘯𝘦𝘺 𝘸𝘢𝘴 𝘳𝘦𝘲𝘶𝘪𝘳𝘦𝘥 𝘵𝘰 𝘨𝘦𝘵 𝘵𝘰 𝘴𝘦𝘳𝘪𝘦𝘴 𝘈 𝘢𝘯𝘥 𝘸𝘩𝘢𝘵 𝘵𝘩𝘦 𝘳𝘪𝘴𝘬/𝘳𝘦𝘸𝘢𝘳𝘥 𝘱𝘳𝘰𝘧𝘪𝘭𝘦 𝘭𝘰𝘰𝘬𝘴 𝘭𝘪𝘬𝘦 𝘢𝘵 𝘵𝘩𝘪𝘴 𝘵𝘪𝘮𝘦.” Happy clients, happy Theresa! 😊 It´s…

  • Investing in Half a Bridge Won´t Get You Across

    One of the most common questions investors ask me:“𝗖𝗮𝗻 𝘁𝗵𝗶𝘀 𝘀𝘁𝗮𝗿𝘁𝘂𝗽 𝗿𝗲𝗮𝗰𝗵 𝗶𝘁𝘀 𝗴𝗼𝗮𝗹𝘀 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗳𝘂𝗻𝗱𝗶𝗻𝗴 𝘁𝗵𝗲𝘆’𝗿𝗲 𝗮𝘀𝗸𝗶𝗻𝗴 𝗳𝗼𝗿?” While it’s tempting to just crunch numbers (capex, burn rate, cost factors), I’ve found that 𝗮𝗻𝗮𝗹𝘆𝘇𝗶𝗻𝗴 𝘁𝗵𝗲 𝘁𝗶𝗺𝗲𝗹𝗶𝗻𝗲 𝗶𝘀 𝗷𝘂𝘀𝘁 𝗮𝘀 𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁: 🧪 Even in the age of AI, 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀 𝗶𝘀 𝘀𝘁𝗶𝗹𝗹 𝘁𝗿𝗶𝗮𝗹 𝗮𝗻𝗱…

  • Media costs are not a reliable indicator for production costs – here is why!

    The price of culture medium in cultivated meat is NOT a reliable indicator of production costs or unit economics. A company with a $10/L growth medium could still have a cheaper end product than one using a $1/L medium. Why? Because price per liter doesn’t tell the full story. Here’s what actually matters: 1️⃣ 𝗠𝗲𝗱𝗶𝘂𝗺…

  • De-risking Startup Investments: A case

    A VC investor recently approached me with a clear and focused request: “We don’t want a full Tech DD, but we’d like your high-level assessment of the technology, specifically its USP and defensibility.” The challenge? The startup they were evaluating was positioned in a 𝗵𝗶𝗴𝗵𝗹𝘆 𝗰𝗿𝗼𝘄𝗱𝗲𝗱 𝘀𝗽𝗮𝗰𝗲, making differentiation and long-term competitive edge critical factors.…

  • How AI platform Evo 2 is speeding up synthetic biology and biomanufacturing

    Deep Tech Investors and Startups this is huge news! The yesterday launched Evo 2 AI model (by Arc Institute and NVIDIA) is set to transform synthetic biology by making genetic design faster, cheaper, and more precise. They say that in only a few seconds Evo 2 can predict how DNA mutations impact organisms and even…

  • Theranos – Today known as one of the worst investments of all time.

    The problem? Their technology was nothing but an empty promise. And yet, it sounded completely feasible: why shouldn’t it be possible to run an extensive health screening with just a few drops of blood? No need to double-check with a scientist, right? We all know how that ended. While a lot of things are possible…

  • Mycelium

    Mycelium

    The magic of fungi Everybody knows mushroom fruit bodies 🍄 whether from the forest or the supermarket (especially if you’re a city kid). But the real magic of fungi happens in the substrate they grow on. Beneath those familiar caps lies a hidden world: a vast system of fine, root-like structures called hyphae. Collectively, this…

  • The Top 200 companies with the power to boost coral conservation and restoration.

    The ocean is key to our planet’s survival. It absorbs 30% of global CO2 emissions, regulates climate, and produces over 50% of the oxygen we breathe. Coral reefs, in particular, are vital ecosystems supporting 25% of marine biodiversity and providing ecosystem services valued at $9.9 trillion annually (source). Yet, despite their importance, ocean protection and…